Table S2. Studies comparing long term outcomes of allogenic and autologous with conventional prostheses.
| First author (Ref.) | Total sample (N) | Number of patients/endocarditis | Mean follow-up/months | Number of aortic valve substitute implanted or repair | Main findings |
|---|---|---|---|---|---|
| Kim 2016 (8) JTCVS | 304 | 304 | 29.4 | CAH [86] | Similar survival between valve substitute. Odds ratio 1.61; 95% confidence interval (CI), 0.73−3.40, P=0.23 (HR 1.10; 95% CI, 0.62−1.94, P=0.75) |
| MP [79] | Reinfection 7.7%. No difference in freedom from reinfection rates (P=.65). CAH did not significantly affect reinfection (HR 1.04; 95% CI, 0.49−2.18, P=0.93) | ||||
| XP [139] | |||||
| Kim 2016 (54) JTCVS | 436 | IVDU 78 Non-IVDU 358 |
29.4 | CAH [86] | Similar survival between group (IVDU vs. Non IDVU). (HR, 0.78; 95% CI, 0.44−1.37). No difference between valve substitute |
| MP [99] | Lower operative mortality in IVDUs [odds ratio, 0.25; 95% confidence interval (CI), 0.06−0.71] | ||||
| XP [206] | Better valve-related complications in IVDUs (HR, 3.82; 95% CI, 1.95−7.49; P<0.001) for higher rates of reinfection (HR, 6.20; 95% CI, 2.56−15.00; P<0.001) | ||||
| Perrotta 2016 (24) Ann Thorac Surg | 84 | 84 | 65 | CAH [56] | 10 yrs similar survival. CAH 58% vs. conventional prosthesis 75% (P=0.17) |
| MP [20] | Higher incidence of reoperation for infection relaps in MP or XP (12.9%) than Ao-H (0%) (P=0.006). Lower incidence of reoperation for SVD in CAH at 10 yrs (5.3%) | ||||
| XP [12] | |||||
| Chiang 2014 (40) JAMA | 2002 | 16 | 128 | MP [9] | No difference in 30-day mortality XP (3%) vs. MP (3%) (P=0.49) |
| XP [7] | No difference survival (P=0.74); 15-year survival XP (60.6%, 95% CI, 56.3−64.9%) vs. MP (62.1%, 95% CI, 58.2−66.0%). HR 0.97 (95% CI, 0.83−1.14) | ||||
| 15 yrs reoperation XP (12.1%) vs. MP (6.9%) (95% CI, 8.8−15.4% vs. 95% CI, 4.2−9.6%. HR: 0.52; 95% CI, 0.36−0.75) | |||||
| Hussain 2014 (63) JTCVS | 775 | 537 | 84 | CAH [357] | 30 days mortality 7% for aortic valve and 14% for aortic and mitral valve IE. Survival at 5 years 75%. Rate of recurrence of infection 5.1% |
| MP [25] | |||||
| XP [139] | |||||
| Grubitzsch 2014 (59) JTCVS | 149 | 96 | 48 | MP [11] | Early death 31.5%. Late death 7.38% |
| XP [80] | Overall and event-free survivals at 10 years were 75% +/− 3.8% and 64% 4.0% | ||||
| Ross Procedure [5] | Freedom from recurrent infection and reoperation at 10 years were 81% +/− 3.6% and 91% +/− 2.6% | ||||
| Manne 2012 (58) Ann Thorac Surg | 428 | 282 | 12 | CAH [173] | Higher 30-day mortality PVE vs. NVE (13% versus 5.6%; P<0.01) |
| MP [24] | No difference in survival NVE vs. PVE (35% versus 29%; P=0.19) | ||||
| XP [84] | Higher 30 days mortality and 1 year mortality for Staphylococcus aureus infection (15% versus 8.4%; P<0.05) and (28% versus 18%; P=0.02) | ||||
| Ross operation [1] | Few reoperation for persistent infection or relapse (2.4%) | ||||
| Ao-R [12] | |||||
| Mayer 2012 (60) Eur J Cardiothorac Surg | 100 | 100 | 31 | MP [10] | Similar 30-day mortality Ao-R 9% vs. Ao-Rpl 18% (P=0.37). Better survival Ao-R (88%) vs. Ao-Rpl (65%) (P=0.047) |
| XP [51] | Higher rate of reoperation Ao-R (35%) vs. Ao-Rpl (10%) (P=0.021) | ||||
| Ross operation [6] | |||||
| Ao-R [33] | |||||
| Nguyen 2010 (53) Eur J Cardiothorac Surg | 167 | 167 | 60 | CAH [77] | 30 day mortality XP (19.4%), Ao-H (7.4%), MP (10.1%) (P=0.27) |
| MP [109] | XP lower overall 5-year survival </=65 yrs [adjusted HR 4.14 (1.27−13.45), P=0.018] but not >65 yrs [adjusted HR: 1.45 (0.35−5.97), P=0.60]. No difference between CAH and MP [HR (0.46, 95% CI (0.15−1.42), P=0.18] | ||||
| XP [31] | |||||
| Klieverik 2009 (14) Ann Thorac Surg | 138 | 138 | 96 | CAH [106] | Higher 30-day mortality for CAH (P=0.25). No difference in survival at 15 yrs (Ao-H 59%±6% and MP 66% ±9% (P=0.68) and freedom from recurrent infection (P=0.29). Higher rates of reoperation for CAH (P=0.02) |
| MP [32] | |||||
| David 2007 (2) JTCVS | 383 | 383 | 73 | CAH [18] | 15 yrs survival 44%. Relapse of IE independent predictors of death (HR 2.2, 95% CI 1.2−3.9) |
| MP [214] | 15 yrs freedom from recurrent IE 86% for all patients without difference between type of valve implanted | ||||
| XP [133] | 15 yrs freedom from reoperation 70% | ||||
| Moon 2001 (3) Ann Thorac Surg | 306 | 306 | 183 | CAH [20] | 20 years survival 46% MP, 41%, XP, 58% CAH; P>0.27 |
| MP [65] | Lower risk of infection relapse without group difference. 5 years 2.1% MP, 2.3% XP, and 3.6% Ao-H; P>0.88. After 5 years 0.5% mechanical prosthesis, 1.1% stented xenograft and 3.1% CAH; P>0.25 | ||||
| XP [221] | 10 and 15 yrs freedom from reoperation for MP 74,6%; 10 and 15 yrs freedom from reoperation for XP 56.6%, 22.6% P>0.64 |